FDA
-
-
-
-
-
-
-
Climb Bio presents initial safety data for CLYM116 at ERA congress
-
-
-
-
-
-
-
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
-
-
-
-
-
-
-
Climb Bio receives FDA fast track designation for kidney drug
-
-
-
-
-
-
-
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Oppenheimer on Climb Bio (CLYM): 'Positive CLYM116 Reveal Carves Path Forward in IgAN'
-
-
-
-
-
-
-
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Climb Bio (CLYM) to be Added to the Nasdaq Biotechnology Index
-
330,680 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

